Dutasteride: a review of its use in the management of prostate disorders.
about
Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasiaAtmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer.The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men.Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men.Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine secretagogue-stimulated cortisol secretionAcne, dairy and cancer: The 5alpha-P link.Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Dutasteride/tamsulosin: in benign prostatic hyperplasia.Anticancer steroids: linking natural and semi-synthetic compounds.Investigational therapies targeted to the treatment of benign prostatic hyperplasia.Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride.Changes in periprostatic adipose tissue induced by 5α-reductase inhibitors.Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin.A dual 5α-reductase inhibitor dutasteride caused reductions in vascular density and area in benign prostatic hyperplasia.Establishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients.Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats
P2860
Q26770425-3CD102D6-E959-41DA-B562-B47329CA28F0Q33446864-CBE27894-FA47-4D88-8D2B-1644CF003E11Q33599598-B6775064-83AE-4524-82FC-96AEB2385B39Q33602452-43D3E017-19A5-48D1-AB09-49CCFEBF09F6Q34905580-340B1C1F-A79B-42B4-B10C-57633C80EDD8Q35024480-0D5C8866-CB60-47F1-91B1-FE28766B6E50Q37273533-320DA475-3C6F-40D7-80CD-1297FB633C53Q37790387-75EF4793-8A39-4F05-90C4-08553E9FCF58Q38006977-C43C033C-08F8-45CE-9100-368944F3DD30Q38059807-69F611FB-D370-41F6-8DBB-CC150EBE6B17Q38073830-B930403A-B5D9-431D-B408-4124335A0622Q38118357-F49F38A0-6844-454C-96F2-54D63F7131BAQ38906372-D0F2E933-281C-48E3-B57A-DF499ABF0D2AQ39243100-425BF44E-DA82-403B-BD33-CEDD7A2898D1Q42103713-C29074F8-C79C-425D-B0FF-16068B7AB000Q44952736-8A149D6D-F42D-46FA-B787-2AC9E04B5036Q53152507-6AF2539F-8309-438E-9CB3-62A90882A252Q57488938-7B316A50-B5A8-4EE0-B8C2-963318B8F53D
P2860
Dutasteride: a review of its use in the management of prostate disorders.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Dutasteride: a review of its use in the management of prostate disorders.
@ast
Dutasteride: a review of its use in the management of prostate disorders.
@en
Dutasteride: a review of its use in the management of prostate disorders.
@nl
type
label
Dutasteride: a review of its use in the management of prostate disorders.
@ast
Dutasteride: a review of its use in the management of prostate disorders.
@en
Dutasteride: a review of its use in the management of prostate disorders.
@nl
prefLabel
Dutasteride: a review of its use in the management of prostate disorders.
@ast
Dutasteride: a review of its use in the management of prostate disorders.
@en
Dutasteride: a review of its use in the management of prostate disorders.
@nl
P1433
P1476
Dutasteride: a review of its use in the management of prostate disorders.
@en
P2093
Susan J Keam
P304
P356
10.2165/00003495-200868040-00008
P577
2008-01-01T00:00:00Z
P6179
1039280559